Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions come as Helus Pharma advances its pipeline of novel serotonergic agonists (NSAs), including programs targeting major depressive disorder and generalized anxiety disorder, aiming to address significant unmet needs in mental health.
Dr. Robert Langer is a renowned figure in biotechnology, holding the title of Institute Professor at MIT and being one of the most cited researchers in history. His work in drug delivery systems has revolutionized medicine. Dr. Stephen Brannan brings extensive experience in CNS clinical development, having led multiple psychiatric drug programs. Their guidance is expected to enhance Helus Pharma's disciplined, evidence-based drug development approach.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical trials for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The company's focus on NSAs—synthetic molecules designed to activate serotonin pathways that promote neuroplasticity—aims to provide durable improvements in mental health. With class-leading data, Helus Pharma intends to improve the treatment landscape for depression, anxiety, and other mental health conditions.
For more details, the full press release is available at https://ibn.fm/CyjTq. About Helus Pharma: The company operates under the commercial name Helus Pharma, formerly Cybin Inc., founded in 2019. It is a clinical-stage pharmaceutical company committed to developing proprietary NSAs. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. More information can be found at www.helus.com.
